SynZeal exhibited at FCE Pharma 2021 at Sau Paulo, Brazil. Our sales and technical team had the opportunity to meet all current and prospective customers. Congratulations to the SynZeal team for making this FCE Pharma 2021 a grand success. We could feel the energy of the people who visited us during this difficult time.
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose resorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin was approved by the FDA on 2014.
SynZeal offers all Dapagliflozin related impurities standards with certified COA and characterization data like IR, Mass, HPLC, purity, NMR & TGA report. We also provide CMR, DEPT and detailed structure characterization report as per requirements. Dapagliflozin related standards are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing.
FCE pharma is highly acclaimed and much anticipanted event for pharmaceutical industry in Latin America. SynZeal will be presenting at FCE Pharma 21 at Booth No G-083 during this event scheduled on Nov 30- Dec 02, 2021 at Sao Paulo Expo, Brazil.
